H-J Lenz

1.8k total citations
21 papers, 1.4k citations indexed

About

H-J Lenz is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, H-J Lenz has authored 21 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Pathology and Forensic Medicine and 9 papers in Molecular Biology. Recurrent topics in H-J Lenz's work include Genetic factors in colorectal cancer (10 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Research and Treatments (2 papers). H-J Lenz is often cited by papers focused on Genetic factors in colorectal cancer (10 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Research and Treatments (2 papers). H-J Lenz collaborates with scholars based in United States, Germany and Japan. H-J Lenz's co-authors include Jan Stoehlmacher, Susan Groshen, Dongyun Yang, W Zhang, Andrew Sherrod, Sue A. Ingles, Sheeja T. Pullarkat, Viviane S. Ghaderi, Denise D. Tsao‐Wei and Robert S. Warren and has published in prestigious journals such as The Lancet, Oncogene and British Journal of Cancer.

In The Last Decade

H-J Lenz

21 papers receiving 1.4k citations

Peers

H-J Lenz

ONCOL

PFM

PRM

Maria Luisa Veronese United States

Hirohide Yoshikawa Japan

Akintunde Akinleye United States

Ronald E. Savage United States

B. F. El-Rayes United States

Giorgia Migliardi Italy

Ji Yuan Wu United States

Qianming Bai China

Paul K. Stockman United Kingdom

Lars Damstrup Denmark

Maria Luisa Veronese United States

H-J Lenz

678 ×0.7

ONCOL

969 ×1.6

262 ×0.9

PFM

340 ×1.3

PRM

190 ×0.8

Citations per year, relative to H-J Lenz H-J Lenz (= 1×) peers Maria Luisa Veronese

Countries citing papers authored by H-J Lenz

Since Specialization

Citations

This map shows the geographic impact of H-J Lenz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H-J Lenz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H-J Lenz more than expected).

Fields of papers citing papers by H-J Lenz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H-J Lenz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H-J Lenz. The network helps show where H-J Lenz may publish in the future.

Co-authorship network of co-authors of H-J Lenz

This figure shows the co-authorship network connecting the top 25 collaborators of H-J Lenz. A scholar is included among the top collaborators of H-J Lenz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H-J Lenz. H-J Lenz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lenz, H-J, et al.. (2022). 1402P Initial results of a cohort of advanced prostate cancer patients in a phase Ia study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody. Annals of Oncology. 33. S1186–S1186. 2 indexed citations

Weisenberger, Daniel J., Gangning Liang, & H-J Lenz. (2017). DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies. Oncogene. 37(5). 566–577. 60 indexed citations

Wu, Anna H., Shu Cao, Diana L. Hanna, et al.. (2017). Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. The Pharmacogenomics Journal. 18(2). 262–269. 2 indexed citations

Sebio, Ana, Sebastian Stintzing, Volker Heinemann, et al.. (2016). A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. The Pharmacogenomics Journal. 18(1). 43–48. 3 indexed citations

Sunakawa, Yu, Shu Cao, Martin D. Berger, et al.. (2016). Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. The Pharmacogenomics Journal. 17(6). 528–534. 8 indexed citations

Ning, Yan, W Zhang, Diana L. Hanna, et al.. (2016). Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients. The Pharmacogenomics Journal. 18(1). 29–34. 44 indexed citations

Szkandera, Joanna, Sereina A. Herzog, Martin Pichler, et al.. (2015). LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy. The Pharmacogenomics Journal. 15(5). 391–396. 12 indexed citations

Sebio, Ana, Souta Matsusaka, W Zhang, et al.. (2015). Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer. The Pharmacogenomics Journal. 16(4). 312–319. 13 indexed citations

Sunakawa, Yu, Shu Cao, Martin D. Berger, et al.. (2015). Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer. The Pharmacogenomics Journal. 17(1). 36–41. 11 indexed citations

10.

Bohanes, Pierre, Dongyun Yang, Fotios Loupakis, et al.. (2014). Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. The Pharmacogenomics Journal. 15(3). 226–234. 12 indexed citations

11.

Maus, Martin, Diana L. Hanna, Clifton Stephens, et al.. (2014). Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. The Pharmacogenomics Journal. 15(4). 354–362. 38 indexed citations

12.

Loupakis, Fotios, Carlotta Antoniotti, Chiara Cremolini, et al.. (2014). Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. The Pharmacogenomics Journal. 14(4). 322–327. 9 indexed citations

13.

Stintzing, Sebastian, W Zhang, Dongyun Yang, et al.. (2014). Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. The Pharmacogenomics Journal. 15(1). 69–76. 26 indexed citations

14.

Páez, David, Armin Gerger, W Zhang, et al.. (2013). Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence. The Pharmacogenomics Journal. 14(2). 142–150. 29 indexed citations

15.

Lee, Yun Sok, In Sil Choi, Yan Ning, et al.. (2012). Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. British Journal of Cancer. 106(11). 1833–1841. 238 indexed citations

16.

Wilson, P. M., Dongyun Yang, Mizutomo Azuma, et al.. (2012). Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). The Pharmacogenomics Journal. 13(5). 410–416. 16 indexed citations

17.

Grimminger, Peter, Carl Barrett, David Lebwohl, et al.. (2011). TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials. The Pharmacogenomics Journal. 12(5). 404–411. 33 indexed citations

18.

Azuma, Mizutomo, W Zhang, Dongyun Yang, et al.. (2010). Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer. The Pharmacogenomics Journal. 11(2). 93–99. 30 indexed citations

19.

Cunningham, David, et al.. (2010). Colorectal cancer – Authors' reply. The Lancet. 376(9738). 331–332. 71 indexed citations

20.

Stoehlmacher, Jan, D J Park, W Zhang, et al.. (2004). A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. British Journal of Cancer. 91(2). 344–354. 302 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact